A phase 1/2 trial in progress of MK-6070 (aka HPN328), a DLL3-targeting T cell engager, as monotherapy or combination therapy for advanced cancers associated with DLL3 expression
Publication Title
SITC Annual Meeting; November 6-10 Houston, TX. 2024: 656
Document Type
Abstract
Publication Date
11-1-2024
Keywords
oregon; chiles
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
Comments
Jain P, Cooper A, Johnson M, Schenk E, Sanborn R, Thompson J, Mamdani H, Dowlati A, Aggarwal R, Sankar K, Gramza A, Beltran H